,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,One Kendall Square,4th Floor Suite B14402 Building 1400 West,Cambridge,MA,02139,United States,617 863 5500,https://www.invivotherapeutics.com,Biotechnology,Healthcare,"InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.",6,"{'maxAge': 1, 'name': 'Dr. Richard M. Toselli', 'age': 64, 'title': 'Pres, CEO, Chief Medical Officer & Director', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 825204, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.14,1.1582,1.13,1.19,1.14,1.1582,1.13,1.19,0.0,0.814661,-0.11018519,5376,5376,18687,7110,7110,1.12,1.36,800,1000,3695485,0.81,7.98,1.2596,1.5439,0.0,0.0,USD,-6270519,0.0,2767418,3105450,17173,9070,1690761600,1693440000,0.0055,0.10738,0.03749,0.8,0.0055,3.728,0.31920603,1672444800,1703980800,1688083200,-9385000,-4.58,-10.8,1:30,1581465600,0.642,NCM,EQUITY,NVIV,NVIV,InVivo Therapeutics Holdings Co,InVivo Therapeutics Holdings Corp.,1289831400,America/New_York,EDT,-14400000,1.19,none,10720000,3.452,-9765000,754000,7.836,9.14,6.513,-0.41779,-0.76955,-7974500,-10216000,0.0,0.0,0.0,USD,
1,One Kendall Square,4th Floor Suite B14402 Building 1400 West,Cambridge,MA,02139,United States,617 863 5500,https://www.invivotherapeutics.com,Biotechnology,Healthcare,"InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.",6,"{'maxAge': 1, 'name': 'Mr. Richard C. Christopher', 'age': 52, 'title': 'CFO & Treasurer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 537816, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.14,1.1582,1.13,1.19,1.14,1.1582,1.13,1.19,0.0,0.814661,-0.11018519,5376,5376,18687,7110,7110,1.12,1.36,800,1000,3695485,0.81,7.98,1.2596,1.5439,0.0,0.0,USD,-6270519,0.0,2767418,3105450,17173,9070,1690761600,1693440000,0.0055,0.10738,0.03749,0.8,0.0055,3.728,0.31920603,1672444800,1703980800,1688083200,-9385000,-4.58,-10.8,1:30,1581465600,0.642,NCM,EQUITY,NVIV,NVIV,InVivo Therapeutics Holdings Co,InVivo Therapeutics Holdings Corp.,1289831400,America/New_York,EDT,-14400000,1.19,none,10720000,3.452,-9765000,754000,7.836,9.14,6.513,-0.41779,-0.76955,-7974500,-10216000,0.0,0.0,0.0,USD,
2,One Kendall Square,4th Floor Suite B14402 Building 1400 West,Cambridge,MA,02139,United States,617 863 5500,https://www.invivotherapeutics.com,Biotechnology,Healthcare,"InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.",6,"{'maxAge': 1, 'name': 'Ms. Heather M. Hamel J.D.', 'age': 32, 'title': 'Chief Legal Officer & Gen. Counsel', 'yearBorn': 1990, 'fiscalYear': 2022, 'totalPay': 446957, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.14,1.1582,1.13,1.19,1.14,1.1582,1.13,1.19,0.0,0.814661,-0.11018519,5376,5376,18687,7110,7110,1.12,1.36,800,1000,3695485,0.81,7.98,1.2596,1.5439,0.0,0.0,USD,-6270519,0.0,2767418,3105450,17173,9070,1690761600,1693440000,0.0055,0.10738,0.03749,0.8,0.0055,3.728,0.31920603,1672444800,1703980800,1688083200,-9385000,-4.58,-10.8,1:30,1581465600,0.642,NCM,EQUITY,NVIV,NVIV,InVivo Therapeutics Holdings Co,InVivo Therapeutics Holdings Corp.,1289831400,America/New_York,EDT,-14400000,1.19,none,10720000,3.452,-9765000,754000,7.836,9.14,6.513,-0.41779,-0.76955,-7974500,-10216000,0.0,0.0,0.0,USD,
3,One Kendall Square,4th Floor Suite B14402 Building 1400 West,Cambridge,MA,02139,United States,617 863 5500,https://www.invivotherapeutics.com,Biotechnology,Healthcare,"InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.",6,"{'maxAge': 1, 'name': 'Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD', 'age': 73, 'title': 'Co-Founder & Member of Scientific Advisory Board', 'yearBorn': 1949, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.14,1.1582,1.13,1.19,1.14,1.1582,1.13,1.19,0.0,0.814661,-0.11018519,5376,5376,18687,7110,7110,1.12,1.36,800,1000,3695485,0.81,7.98,1.2596,1.5439,0.0,0.0,USD,-6270519,0.0,2767418,3105450,17173,9070,1690761600,1693440000,0.0055,0.10738,0.03749,0.8,0.0055,3.728,0.31920603,1672444800,1703980800,1688083200,-9385000,-4.58,-10.8,1:30,1581465600,0.642,NCM,EQUITY,NVIV,NVIV,InVivo Therapeutics Holdings Co,InVivo Therapeutics Holdings Corp.,1289831400,America/New_York,EDT,-14400000,1.19,none,10720000,3.452,-9765000,754000,7.836,9.14,6.513,-0.41779,-0.76955,-7974500,-10216000,0.0,0.0,0.0,USD,
4,One Kendall Square,4th Floor Suite B14402 Building 1400 West,Cambridge,MA,02139,United States,617 863 5500,https://www.invivotherapeutics.com,Biotechnology,Healthcare,"InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.",6,"{'maxAge': 1, 'name': 'Dr. Joseph Philip Vacanti M.D.', 'age': 73, 'title': 'Co-Founder', 'yearBorn': 1949, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.14,1.1582,1.13,1.19,1.14,1.1582,1.13,1.19,0.0,0.814661,-0.11018519,5376,5376,18687,7110,7110,1.12,1.36,800,1000,3695485,0.81,7.98,1.2596,1.5439,0.0,0.0,USD,-6270519,0.0,2767418,3105450,17173,9070,1690761600,1693440000,0.0055,0.10738,0.03749,0.8,0.0055,3.728,0.31920603,1672444800,1703980800,1688083200,-9385000,-4.58,-10.8,1:30,1581465600,0.642,NCM,EQUITY,NVIV,NVIV,InVivo Therapeutics Holdings Co,InVivo Therapeutics Holdings Corp.,1289831400,America/New_York,EDT,-14400000,1.19,none,10720000,3.452,-9765000,754000,7.836,9.14,6.513,-0.41779,-0.76955,-7974500,-10216000,0.0,0.0,0.0,USD,
